AstraZeneca, said: "Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also delivered nine positive high value Phase III ...

Rare Disease Revenue: $8.8 billion in 2024, up 16%. AstraZeneca PLC (NASDAQ:AZN) reported a strong financial performance in 2024, with total revenue up 21% and core EPS up 19%, indicating robust ...

Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...

Pharmaceutical giant AstraZeneca announced its fourth quarter and full year 2024 earnings on Thursday. Product sales for the fourth quarter came up to $13.4 billion (€12.9bn), which was a rise ...

(MENAFN- The Arabian Post) DUBAI, UAE – media OutReach Newswire – 28 January 2025 – AstraZeneca ... place to work across the Middle East for 2024 according to the annual prestigious ...

AstraZeneca continues to fully cooperate with the Chinese authorities. In December 2024 AstraZeneca announced the appointment of Iskra Reic as Executive Vice President, International, which ...

2024 was a very strong year for our company ... which to the best of our knowledge relates to Imfinzi and Imjudo. So if actually AstraZeneca was found liable, a fine of between one to five ...

BioPharmaceuticals Revenue: $21.9 billion in 2024, up 21%. Rare Disease Revenue: $8.8 billion in 2024, up 16%. AstraZeneca PLC (NASDAQ:AZN) reported a strong financial performance in 2024, with total ...

Dubai, UAE – AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been recognized as the second-best place to work across the Middle East for 2024 according to the annual ...

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary Financial performance for FY 2024 (Growth numbers at constant exchange rates) Total Revenue up 21% to $54,073m ...

Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary Financial performance for FY 2024 (Growth numbers at constant exchange ...